GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » Forward PE Ratio

Changzhou Qianhong Biopharma Co (SZSE:002550) Forward PE Ratio : 0.00 (As of May. 10, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co Forward PE Ratio?

Changzhou Qianhong Biopharma Co's Forward PE Ratio for today is 0.00.

Changzhou Qianhong Biopharma Co's PE Ratio without NRI for today is 38.73.

Changzhou Qianhong Biopharma Co's PE Ratio for today is 37.24.


Changzhou Qianhong Biopharma Co Forward PE Ratio Historical Data

The historical data trend for Changzhou Qianhong Biopharma Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Changzhou Qianhong Biopharma Co Forward PE Ratio Chart

Changzhou Qianhong Biopharma Co Annual Data
Trend
Forward PE Ratio

Changzhou Qianhong Biopharma Co Quarterly Data
Forward PE Ratio

Competitive Comparison of Changzhou Qianhong Biopharma Co's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Changzhou Qianhong Biopharma Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Changzhou Qianhong Biopharma Co's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Changzhou Qianhong Biopharma Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Changzhou Qianhong Biopharma Co's Forward PE Ratio falls into.



Changzhou Qianhong Biopharma Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Changzhou Qianhong Biopharma Co  (SZSE:002550) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Changzhou Qianhong Biopharma Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Changzhou Qianhong Biopharma Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Changzhou Qianhong Biopharma Co (SZSE:002550) Business Description

Traded in Other Exchanges
N/A
Address
Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022
Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.

Changzhou Qianhong Biopharma Co (SZSE:002550) Headlines

No Headlines